Publication:
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinolineand uracil derivatives

dc.contributor.authorVeda Prachayasittikulen_US
dc.contributor.authorRatchanok Pingaewen_US
dc.contributor.authorChanin Nantasenamaten_US
dc.contributor.authorSupaluk Prachayasittikulen_US
dc.contributor.authorSomsak Ruchirawaten_US
dc.contributor.authorVirapong Prachayasittikulen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.contributor.otherChulabhorn Research Instituteen_US
dc.contributor.otherChulabhorn Graduate Instituteen_US
dc.date.accessioned2018-11-09T02:35:02Z
dc.date.available2018-11-09T02:35:02Z
dc.date.issued2014-08-14en_US
dc.description.abstractPurpose: Estrogens play important roles in the pathogenesis and progression of breast cancer as well as estrogen-related diseases. Aromatase is a key enzyme in the rate-limiting step of estrogen production, in which its inhibition is one strategy for controlling estrogen levels to improve prognosis of estrogen-related cancers and diseases. Herein, a series of metal (Mn, Cu, and Ni) complexes of 8-hydroxyquinoline (8HQ) and uracil derivatives (4-9) were investigated for their aromatase inhibitory and cytotoxic activities. Methods: The aromatase inhibition assay was performed according to a Gentest™ kit using CYP19 enzyme, wherein ketoconazole and letrozole were used as reference drugs. The cytotoxicity was tested on normal embryonic lung cells (MRC-5) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: Only Cu complexes (6 and 9) exhibited aromatase inhibitory effect with IC500.30 and 1.7 μM, respectively. Cytotoxicity test against MRC-5 cells showed that Mn and Cu complexes (5 and 6), as well as free ligand 8HQ, exhibited activity with IC50range 0.74-6.27 μM. Conclusion: Cu complexes (6 and 9) were found to act as a novel class of aromatase inhibitor. Our findings suggest that these 8HQ-Cu-uracil complexes are promising agents that could be potentially developed as a selective anticancer agent for breast cancer and other estrogen-related diseases. © 2014 Prachayasittikul et al.en_US
dc.identifier.citationDrug Design, Development and Therapy. Vol.8, (2014), 1089-1096en_US
dc.identifier.doi10.2147/DDDT.S67300en_US
dc.identifier.issn11778881en_US
dc.identifier.other2-s2.0-84906242390en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34216
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84906242390&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleInvestigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinolineand uracil derivativesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84906242390&origin=inwarden_US

Files

Collections